180 Wealth Advisors, LLC Altimmune, Inc. Transaction History

180 Wealth Advisors, LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Jul 30, 2025	SELL	$3.5 - $7.71 $2,712 - $5,975	-775 Reduced 6.42%	11,300 $43,000
Q1 2025 Apr 08, 2025	BUY	$5.0 - $7.45 $6,100 - $9,089	1,220 Added 11.24%	12,075 $64,000
Q4 2024 Jan 13, 2025	BUY	$6.02 - $9.85 $65,347 - $106,921	10,855 New	10,855 $78,000

195

40.1M

3.82M

2.8M

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $204M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of 180 Wealth Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on 180 Wealth Advisors, LLC with notifications on news.